Is GSK or RVMD more profitable?

GSK has a net margin of 17.82% compared to Revolution Medicines' net margin of 0.00%. GSK's return on equity of 44.28% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Revolution Medicines N/A -83.22% -59.06%

Does the media favor GSK or RVMD?

In the previous week, GSK had 13 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for GSK and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat GSK's score of 0.20 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RVMD or SNY?

In the previous week, Sanofi had 4 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for Sanofi and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Sanofi's score of 0.76 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sanofi 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARGX or RVMD?

In the previous week, argenex had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 10 mentions for argenex and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat argenex's score of 0.93 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate RVMD or TAK?

Revolution Medicines presently has a consensus price target of $144.00, indicating a potential downside of 22.65%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Revolution Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 1 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.95 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer RVMD or TAK?

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Revolution Medicines. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Takeda Pharmaceutical's score of 0.65 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TEVA or RVMD?

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Teva Pharmaceutical Industries' score of 1.45 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 15 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Revolution Medicines (RVMD) Competitors

$186.16 +6.98 (+3.90%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$184.55 -1.61 (-0.86%)

As of 07/17/2026 07:58 PM Eastern

Compare

RVMD vs. GSK, SNY, ARGX, TAK, and TEVA

Should you buy Revolution Medicines stock or one of its competitors? MarketBeat compares Revolution Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revolution Medicines include GSK (GSK), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Revolution Medicines compare to GSK?

GSK (NYSE:GSK) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

15.7% of GSK shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GSK has a net margin of 17.82% compared to Revolution Medicines' net margin of 0.00%. GSK's return on equity of 44.28% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Revolution Medicines	N/A	-83.22%	-59.06%

GSK has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.43	$7.54B	$3.85	13.46
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

GSK has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, GSK had 13 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for GSK and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat GSK's score of 0.20 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 2.30%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 22.65%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

GSK beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Sanofi?

Revolution Medicines (NASDAQ:RVMD) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sanofi has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Sanofi	$47.35B	2.29	$8.84B	$3.58	12.47

Revolution Medicines presently has a consensus price target of $144.00, suggesting a potential downside of 22.65%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 10.84%. Given Sanofi's higher possible upside, analysts clearly believe Sanofi is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has a net margin of 16.95% compared to Revolution Medicines' net margin of 0.00%. Sanofi's return on equity of 13.39% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Sanofi	16.95%	13.39%	7.58%

Revolution Medicines has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

In the previous week, Sanofi had 4 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for Sanofi and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Sanofi's score of 0.76 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sanofi	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Revolution Medicines on 9 of the 15 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

argenex (NASDAQ:ARGX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, argenex had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 10 mentions for argenex and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat argenex's score of 0.93 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.60	$1.29B	$22.46	38.31
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

60.3% of argenex shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

argenex currently has a consensus price target of $1,037.61, suggesting a potential upside of 20.58%. Revolution Medicines has a consensus price target of $144.00, suggesting a potential downside of 22.65%. Given argenex's higher possible upside, analysts plainly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

argenex has a net margin of 31.31% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 44.37% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Revolution Medicines	N/A	-83.22%	-59.06%

argenex has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Summary

argenex beats Revolution Medicines on 9 of the 14 factors compared between the two stocks.

How does Revolution Medicines compare to Takeda Pharmaceutical?

Revolution Medicines (NASDAQ:RVMD) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Revolution Medicines presently has a consensus price target of $144.00, indicating a potential downside of 22.65%. Given Revolution Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Revolution Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Revolution Medicines. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Takeda Pharmaceutical's score of 0.65 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	43.98

Takeda Pharmaceutical has a net margin of 4.31% compared to Revolution Medicines' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 11.20% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Revolution Medicines and Takeda Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.13	$1.41B	$1.33	24.06
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Revolution Medicines. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 5 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.70 beat Teva Pharmaceutical Industries' score of 1.45 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, indicating a potential upside of 30.57%. Revolution Medicines has a consensus price target of $144.00, indicating a potential downside of 22.65%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.58B	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-26.33	21.03	27.25	23.92
Price / Sales	N/A	177.66	517.85	89.30
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	22.06	8.26	10.69	6.18
Net Income	-$1.13B	$23.83M	$3.59B	$332.29M
7 Day Performance	-0.39%	-3.47%	-2.20%	-2.05%
1 Month Performance	14.22%	2.69%	1.63%	-2.18%
1 Year Performance	386.06%	45.93%	25.64%	17.67%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	1.975 of 5 stars	$186.16 +3.9%	$144.00 -22.6%	+386.1%	$39.58B	N/A	N/A	250	Positive News
GSK GSK	2.9592 of 5 stars	$52.30 -0.9%	$53.00 +1.3%	+42.8%	$106.76B	$43.07B	13.59	66,841	Trending News Dividend Cut
SNY Sanofi	3.9621 of 5 stars	$44.00 +1.1%	$49.50 +12.5%	-7.6%	$105.46B	$49.35B	12.29	74,846	News Coverage Analyst Downgrade
ARGX argenex	4.6365 of 5 stars	$876.25 -0.2%	$1,037.61 +18.4%	+52.4%	$54.58B	$4.25B	39.01	1,863	News Coverage Upcoming Earnings
TAK Takeda Pharmaceutical	1.9215 of 5 stars	$16.49 -0.4%	N/A	+18.9%	$52.70B	$28.32B	42.28	47,000	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. GSK, SNY, ARGX, TAK, and TEVA

How does Revolution Medicines compare to GSK?

Summary

How does Revolution Medicines compare to Sanofi?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. GSK, SNY, ARGX, TAK, and TEVA

How does Revolution Medicines compare to GSK?

Do institutionals & insiders believe in GSK or RVMD?

Is GSK or RVMD more profitable?

Which has higher earnings and valuation, GSK or RVMD?

Which has more volatility & risk, GSK or RVMD?

Does the media favor GSK or RVMD?

Do analysts rate GSK or RVMD?

Summary

How does Revolution Medicines compare to Sanofi?

Do insiders and institutionals hold more shares of RVMD or SNY?

Which has preferable valuation and earnings, RVMD or SNY?

Do analysts recommend RVMD or SNY?

Is RVMD or SNY more profitable?

Which has more risk & volatility, RVMD or SNY?

Does the media prefer RVMD or SNY?

Summary

How does Revolution Medicines compare to argenex?

Does the media refer more to ARGX or RVMD?

Which has preferable earnings and valuation, ARGX or RVMD?

Do institutionals and insiders believe in ARGX or RVMD?

Do analysts recommend ARGX or RVMD?

Is ARGX or RVMD more profitable?

Which has more risk and volatility, ARGX or RVMD?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Do analysts rate RVMD or TAK?

Does the media prefer RVMD or TAK?

Which has more volatility and risk, RVMD or TAK?

Which has higher valuation and earnings, RVMD or TAK?

Is RVMD or TAK more profitable?

Do insiders & institutionals believe in RVMD or TAK?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Which has stronger valuation & earnings, TEVA or RVMD?

Does the media favor TEVA or RVMD?

Do institutionals & insiders believe in TEVA or RVMD?

Which has more risk and volatility, TEVA or RVMD?

Do analysts rate TEVA or RVMD?

Is TEVA or RVMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools